Nutriband reports Q3 EPS (14c) vs. (23c) last year

Reports Q3 revenue $620,000 vs. $280,000 last year. "Once again, we have had a record quarter for our revenue generating subsidiaries. Building on these revenue streams remains an important focus for us as we continue to develop AVERSA Fentanyl.," commented Gareth Sheridan, CEO of Nutriband. "According to the assessment by Health Advances, AVERSA Fentanyl could reach peak annual sales of between $80 to $200 million. If the entire transdermal fentanyl market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater. We are continually thankful to our shareholders for their ongoing support as we continue to execute on our vision of commercializing AVERSA”.